Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AB680 (Quemliclustat) in Healthy Volunteers
NCT03677973Phase 1Completed
- Sponsor
- Arcus Biosciences
- Start
- Oct 2018
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of quemliclustat in pancreatic ductal adenocarcinoma (PDAC), gastrointestinal neoplasms, colorectal cancer (CRC) and 1 more (2 arms), sponsored by Arcus Biosciences. Primary endpoints: Number of Participants with Treatment Emergent Adverse Events, AB680 Peak Plasma Concentration and 1 more. Started Oct 2018; status: completed.
02
Drugs
quemliclustat
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)gastrointestinal neoplasmscolorectal cancer (CRC)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03677973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03677973.